SCYNEXIS Inc

135A

Company Profile

  • Business description

    SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

  • Contact

    1 Evertrust Plaza
    13th Floor
    Jersey CityNJ07302 - 6548
    USA

    T: +1 201 884-5485

    E: [email protected]

    https://www.scynexis.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2025

    Employees

    29

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,796.8029.60-0.34%
CAC 407,723.4727.200.35%
DAX 4024,073.67286.221.20%
Dow JONES (US)44,406.36422.17-0.94%
FTSE 1008,806.5316.38-0.19%
HKSE23,887.8328.23-0.12%
NASDAQ20,412.52188.59-0.92%
Nikkei 22539,716.05128.370.32%
NZX 50 Index12,710.1254.83-0.43%
S&P 5006,229.9849.37-0.79%
S&P/ASX 2008,561.0028.30-0.33%
SSE Composite Index3,473.130.810.02%

Market Movers